VAQTA 25 [iU]/.5mL

VAQTA 25 [iU]/.5mL is an inactivated hepatitis A vaccine designed for intramuscular administration. It is used to prevent hepatitis A infection, a viral liver disease. This vaccine is suitable for individuals at risk of exposure to the virus.

The VAQTA 25 [iU]/.5mL vaccine is primarily used to prevent hepatitis A, a viral infection that can cause liver inflammation. It is often recommended for people traveling to areas with high rates of hepatitis A, as well as for those who may be exposed to the virus through their work or lifestyle. The vaccine works by stimulating the body's immune system to produce antibodies against the hepatitis A virus.

Common effects of the VAQTA 25 [iU]/.5mL vaccine may include soreness, redness, or swelling at the injection site. Some individuals might experience mild fever, headache, or fatigue following vaccination. These effects are generally short-lived and resolve on their own.

Before receiving the VAQTA 25 [iU]/.5mL vaccine, inform your healthcare provider about any allergies, especially to yeast or neomycin, as these are components of the vaccine. Individuals with weakened immune systems should consult their healthcare provider before vaccination. Always follow the storage and handling instructions provided with the vaccine.

The VAQTA 25 [iU]/.5mL vaccine may interact with certain medications that affect the immune system. It is important to discuss all current medications with a healthcare provider before receiving the vaccine. Alcohol consumption does not typically interact with the vaccine, but maintaining overall health is advisable.